Heptares Therapeutics Limited

Nxera Pharma UK Limited

Astrazeneca Ab (publ)

Other

Allergan Pharmaceuticals International Limited

Cbt Development Limited

Proximagen Group Limited

Giles Albert Brown

Miles Stuart Congreve

Benjamin Gerald Tehan

Mark Pickworth

Julie Elaine Cansfield

Barry John Teobald

Michael Alistair O'Brien

Mark David Rackham

Jonathan Stephen Mason

Nigel Alan Swain

Stephen Philippe Andrews

Christine Mary Richardson

John Andrew Christopher

Michael Higginbottom

Shawn Donald Johnstone

Karl Henrik Edman

Francesca Deflorian

Sarah Joanne Bucknell

David Livermore

Mark Mills

Kathryn White

Anil Patel

Hongming Chen

Joseph W Boyd

Frank Xinhe Wu

Dean Gordon Brown

Anne Mary Stephenson

Andrew David Cansfield

John Graham Cumming

Roland Werner Burli

Conor Scully

Gregory R Ott

Stephen Paul Watson

Michael Alistair O'brien

Andrea Bortolato

Iain Simpson

Charlotte Fieldhouse

Geraint Jones

Andrew William Phillips

Edward D Savory

Giovanni Bottegoni

Jaqueline Ouzman

Emma J Chapman

Viet-Anh A Horgan

Viet-Anh Anne Horgan (Nee Nguyen)

Rebecca Paul

Paul Mcgee

Kathryn Oliver

Lee Patient

Edward Daniel Savory

Andrew Graham Cole

Allison Carley

Alison Stewart

Barry John Teobold

The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein R, AA, AA2, LysR, X and Y are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide-1 (GLP-1) receptors.

GLP-1 receptor antagonists

The disclosures herein relate to novel compounds of Formula (1); and salts thereof, wherein A, A, Q, X, R, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

CGRP antagonist compounds

The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R; R; Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Orexin 1 receptor antagonists

This invention relates to compounds that are agonists of the muscarinic Mand/or Mreceptor and which are useful in the treatment of diseases mediated by the muscarinic Mand Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where p; q; X; X; Y; R; R; R; R; Rand Rare as defined herein.

Oxime compounds as agonists of the muscarinic Mand/or Mreceptor

The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R; R; R; Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Oxexin 1 receptor antagonists

Pyrazole derivatives as H4 antagonist compounds

The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

This invention related to compounds having activity as muscarinic Mor Mand Mreceptor agonists which are useful in the treatment of diseases mediated by the muscarinic Mand Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where X; X; X; X; Y; Z; n, Rand Rare defined herein.

Quinolinone and benzoxazine derivatives as muscarinic Mand/or Mreceptor agonists

This invention relates to compounds that are agonists of the muscarinic Mreceptor and which are useful in the treatment of muscarinic Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q, W, Z, Y, X, X, R, R, Rand Rare as defined herein.

Muscarinic receptor agonists

According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A-Aor, particularly, the Areceptor. A process for the preparation of the compound, pharmaceutical compositions comprising the compound, and methods of treatment comprising administration of an effective amount of the compound are also disclosed.

1,2,4-triazine-4-amine derivatives

This invention relates to compounds that are agonists of the muscarinic Mreceptor and/or Mreceptor and which are useful in the treatment of muscarinic M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R, R, R, Rand Rare as defined herein.

Muscarinic agonists

The disclosures herein relate to novel compounds of formula (1):(1) and salts thereof, wherein W, X, Y, Z, m, n, q, R, R, R, R, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with somatostatin receptors.

Cyclohexapeptides as selective somatostatin SST5 receptor agonists

This invention relates to compounds that are agonists of the muscarinic Mand/or Mreceptor and which are useful in the treatment of diseases mediated by the muscarinic Mand Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where X; X; Rand Rare as defined herein.

Bicyclic aza compounds as muscarinic Mand/or Mreceptor agonists

This invention relates to compounds that are agonists of the muscarinic Mreceptor or Mand Mreceptors and which are useful in the treatment of muscarinic Mor M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q, Q, R, p, V, Q, Q, X, Xand W are defined herein.

Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists

This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R-Rare as defined herein.

Muscarinic M1 receptor agonists

Growing community of inventors

Cambridge, United Kingdom

Giles Albert Brown